Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment-Reference-Cited by-同舟云学术

Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment

Published:2023-09 Issue:9 Volume:42 Page:113098
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Yabushita Tomohiro,Chinen Takumi,Nishiyama Atsuya,Asada Shuhei,Shimura Ruka,Isobe Tomoya,Yamamoto Keita,Sato Naru,Enomoto Yutaka,Tanaka Yosuke,Fukuyama Tomofusa,Satoh Hitoshi,Kato Keiko,Saitoh Kaori,Ishikawa Takamasa,Soga Tomoyoshi,Nannya Yasuhito,Fukagawa Tatsuo,Nakanishi Makoto,Kitagawa Daiju,Kitamura Toshio,Goyama Susumu^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference90 articles.

1. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study;Kantarjian;Cancer,2006

2. Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

3. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial;Steensma;J. Clin. Oncol.,2009

4. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia;Kantarjian;J. Clin. Oncol.,2012

5. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia;DiNardo;N. Engl. J. Med.,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advancements in biomarkers, therapeutics, and associated challenges in acute myeloid leukemia;Annals of Hematology;2024-08-29

2. Identification of epigenetic modifiers essential for growth and survival of AML1/ETO‐positive leukemia;International Journal of Cancer;2024-08-15

3. Latent mitotic vulnerability of AML cells induced by therapeutic agents;2024-07-01

4. Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency;International Journal of Hematology;2024-05-03

5. Upregulated cholesterol biosynthesis facilitates the survival of methylation-retaining AML cells following decitabine treatment;2024-02-01